Literature DB >> 22431453

Quantitation of melatonin and n-acetylserotonin in human plasma by nanoflow LC-MS/MS and electrospray LC-MS/MS.

Melissa D Carter1, M Wade Calcutt, Beth A Malow, Kristie L Rose, David L Hachey.   

Abstract

Melatonin (MEL) and its chemical precursor N-acetylserotonin (NAS) are believed to be potential biomarkers for sleep-related disorders. Measurement of these compounds, however, has proven to be difficult due to their low circulating levels, especially that of NAS. Few methods offer the sensitivity, specificity and dynamic range needed to monitor MEL and its precursors and metabolites in small blood samples, such as those obtained from pediatric patients. In support of our ongoing study to determine the safety, tolerability and PK dosing strategies for MEL in treating insomnia in children with autism spectrum disorder, two highly sensitive LC-MS/MS assays were developed for the quantitation of MEL and precursor NAS at pg/mL levels in small volumes of human plasma. A validated electrospray ionization (ESI) method was used to quantitate high levels of MEL in PK studies, and a validated nanospray (nESI) method was developed for quantitation of MEL and NAS at endogenous levels. In both assays, plasma samples were processed by centrifugal membrane dialysis after addition of stable isotopic internal standards, and the components were separated by either conventional LC using a Waters SymmetryShield RP18 column (2.1 × 100  mm, 3.5 µm) or on a polyimide-coated, fused-silica capillary self-packed with 17 cm AquaC18 (3 µm, 125 Å). Quantitation was done using the SRM transitions m/z 233 → 174 and m/z 219 → 160 for MEL and NAS, respectively. The analytical response ratio versus concentration curves were linear for MEL (nanoflow LC: 11.7-1165  pg/mL, LC: 1165-116,500  pg/mL) and for NAS (nanoflow LC: 11.0-1095  pg/mL).
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431453      PMCID: PMC3319463          DOI: 10.1002/jms.2051

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  19 in total

1.  Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection.

Authors:  Vittoria Rizzo; Camillo Porta; Mauro Moroni; Enrico Scoglio; Remigio Moratti
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-07-05       Impact factor: 3.205

2.  Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism.

Authors:  I Nir; D Meir; N Zilber; H Knobler; J Hadjez; Y Lerner
Journal:  J Autism Dev Disord       Date:  1995-12

3.  Effects of melatonin on orphanin FQ/nociceptin-induced hyperalgesia in mice.

Authors:  Ting Wang; Shi-Rong Li; Xu Dai; Ya-Li Peng; Qiang Chen; Rui Wang
Journal:  Brain Res       Date:  2006-03-29       Impact factor: 3.252

4.  Evidence of pineal endocrine hypofunction in autistic children.

Authors:  Gaia Kulman; Paolo Lissoni; Franco Rovelli; Maria Grazia Roselli; Fernando Brivio; Pierangelo Sequeri
Journal:  Neuro Endocrinol Lett       Date:  2000       Impact factor: 0.765

5.  High-affinity binding of melatonin to hemoglobin.

Authors:  E Gilad; N Zisapel
Journal:  Biochem Mol Med       Date:  1995-12

Review 6.  Circadian sleep-wake rhythm disturbances in end-stage renal disease.

Authors:  Birgit C P Koch; J Elsbeth Nagtegaal; Gerard A Kerkhof; Piet M ter Wee
Journal:  Nat Rev Nephrol       Date:  2009-05-26       Impact factor: 28.314

7.  Abnormal melatonin synthesis in autism spectrum disorders.

Authors:  J Melke; H Goubran Botros; P Chaste; C Betancur; G Nygren; H Anckarsäter; M Rastam; O Ståhlberg; I C Gillberg; R Delorme; N Chabane; M-C Mouren-Simeoni; F Fauchereau; C M Durand; F Chevalier; X Drouot; C Collet; J-M Launay; M Leboyer; C Gillberg; T Bourgeron
Journal:  Mol Psychiatry       Date:  2007-05-15       Impact factor: 15.992

8.  Measurement of melatonin in body fluids: standards, protocols and procedures.

Authors:  Eduardo Alves de Almeida; Paolo Di Mascio; Tatsuo Harumi; D Warren Spence; Adam Moscovitch; Rüdiger Hardeland; Daniel P Cardinali; Gregory M Brown; S R Pandi-Perumal
Journal:  Childs Nerv Syst       Date:  2010-11-21       Impact factor: 1.475

9.  Cytogenetic abnormalities and fragile-X syndrome in Autism Spectrum Disorder.

Authors:  Kavita S Reddy
Journal:  BMC Med Genet       Date:  2005-01-18       Impact factor: 2.103

10.  Determination of melatonin in biological fluids in the presence of the melatonin agonist S 20098: comparison of immunological techniques and GC-MS methods.

Authors:  G Simonin; L Bru; E Lelièvre; J P Jeanniot; N Bromet; B Walther; C Boursier-Neyret
Journal:  J Pharm Biomed Anal       Date:  1999-11       Impact factor: 3.935

View more
  9 in total

1.  Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep.

Authors:  Suzanne E Goldman; Karen W Adkins; M Wade Calcutt; Melissa D Carter; Robert L Goodpaster; Lily Wang; Yaping Shi; Helen J Burgess; David L Hachey; Beth A Malow
Journal:  J Autism Dev Disord       Date:  2014-10

2.  Characterization of serotonin and N-acetylserotonin systems in the human epidermis and skin cells.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Konrad Kleszczyński; Igor Semak; Zorica Janjetovic; Trevor Sweatman; Cezary Skobowiat; Jeffery D Steketee; Zongtao Lin; Arnold Postlethwaite; Wei Li; Russel J Reiter; Desmond J Tobin
Journal:  J Pineal Res       Date:  2019-12-20       Impact factor: 13.007

3.  Relative quantification of amine-containing metabolites using isobaric N,N-dimethyl leucine (DiLeu) reagents via LC-ESI-MS/MS and CE-ESI-MS/MS.

Authors:  Ling Hao; Xuefei Zhong; Tyler Greer; Hui Ye; Lingjun Li
Journal:  Analyst       Date:  2015-01-21       Impact factor: 4.616

4.  Daily Rhythm in Plasma N-acetyltryptamine.

Authors:  Peter S Backlund; Henryk F Urbanski; Mark A Doll; David W Hein; Marjan Bozinoski; Christopher E Mason; Steven L Coon; David C Klein
Journal:  J Biol Rhythms       Date:  2017-05-03       Impact factor: 3.182

Review 5.  Melatonin and the Brain-Heart Crosstalk in Neurocritically Ill Patients-From Molecular Action to Clinical Practice.

Authors:  Artur Bekała; Włodzimierz Płotek; Dorota Siwicka-Gieroba; Joanna Sołek-Pastuszka; Romuald Bohatyrewicz; Jowita Biernawska; Katarzyna Kotfis; Magdalena Bielacz; Andrzej Jaroszyński; Wojciech Dabrowski
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

Review 6.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 7.  Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases.

Authors:  Andreea Iulia Socaciu; Răzvan Ionuţ; Mihai Adrian Socaciu; Andreea Petra Ungur; Maria Bârsan; Angelica Chiorean; Carmen Socaciu; Armand Gabriel Râjnoveanu
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

8.  Heritability of the melatonin synthesis variability in autism spectrum disorders.

Authors:  Marion Benabou; Thomas Rolland; Claire S Leblond; Gaël A Millot; Guillaume Huguet; Richard Delorme; Marion Leboyer; Cécile Pagan; Jacques Callebert; Erik Maronde; Thomas Bourgeron
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

9.  Discovery of Biomarkers and Potential Mechanisms of Agarwood Incense Smoke Intervention by Untargeted Metabolomics and Network Pharmacology.

Authors:  Meiyue Dong; Haitao Du; Xueling Li; Ling Zhang; Xiaoming Wang; Zhenguo Wang; Haiqiang Jiang
Journal:  Drug Des Devel Ther       Date:  2022-01-26       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.